ClinicalTrials.gg
RecruitingNCT04787198Updated Feb 2, 2024

Investigating Composite Biomarkers for Pain Catastrophizing

An interventional study of hypertonic saline and isotonic saline in Pain, Acute, sponsored by Aalborg University. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Aalborg University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Acute Pain with a site in Denmark — 3 open to participants now, 4 under way, none of them phase 3. Acute Pain · Denmark.

Planned enrollment
10th of 15
44 · median 50
Started
2022
with 3 others
No phase
7 of 19
2 open now
Registered
9th of 19
by date
Lead sponsor
4 of 19
Aalborg University

Among the 19 studies in Acute Pain with a site in Denmark, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2022, is one of 7 with no phase, and was the 9th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

3 of the 19 studies in Acute Pain with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Acute Pain with a site in Denmark, or all of them as a file.
02

Study summary

Pain is a complex, multidimensional, and subjective experience; and although, investigators use a single word "pain", to describe our perception, multiple mechanisms contribute to the generation and maintenance of pain. To help diagnosing and improving pain management, there is a need for developing tools. These tools may include measurements of substances, or biomarkers, in the blood; e.g. small molecules called microRNA and proteins. In these experiments, the investigators would like to investigate how the psychological response to stress and pain alters the impulses in the brain and the content of microRNA and proteins in the blood. The future aim is to identify patients in high risk of developing and maintaining chronic pain and to be able to treat chronic pain efficiently.

03

Conditions studied

  • Pain, Acute

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men and women in the age 18-80 years
  • Speak and understand English

Exclusion criteria

Exclusion Criteria:

  • Acute and chronic pain
  • Pregnancy or breastfeeding
  • Drug addiction defined as the use of cannabis, opioids or other drugs
  • Present or previous history of neurological, dermatological, immunological, musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. Neuropathy, muscular pain in the upper extremities, etc.)
  • Focal and generalized seizure
  • Surgery or any other therapy for epilepsy
  • Present or previous AEDs (anti-epileptic drugs) administration
  • Present or previous use of epileptic devices (\<1 year prior the enrolment)
  • Lack of ability to cooperate
  • Current use of medications that may affect the trial, such as antipsychotics and pain killers as well as systemic or topical and anti-inflammatory drugs.
  • Skin diseases
  • Consumption of alcohol or painkillers 24 hours before the study days and between these
  • Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    hypertonic saline

    Drug: hypertonic saline

  • Placebo comparator
    isotonic saline

    Drug: isotonic saline

Interventions

  • Drughypertonic saline

    The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .

  • Drugisotonic saline

    The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.

06

What researchers measure

Primary outcomes

  1. Oscillations of the main electroencephalogram (EEG) frequency

    Electroencephalographic (EEG) recording will be performed placing a 64-electrodes cap over the scalp according to the 10-20 international system. Oscillations of the main EEG frequency bands (delta, alpha, beta, gamma) from the frontal and parietal lobes will be detected and correlated to the individual pain rate as well as the dimensions of the psychological questionnaires.

    Time frame: 10 minutes of recording before isotonic/hypertonic injection

  2. Oscillations of the main electroencephalogram (EEG) frequency

    Electroencephalographic (EEG) recording will be performed placing a 64-electrodes cap over the scalp according to the 10-20 international system. Oscillations of the main EEG frequency bands (delta, alpha, beta, gamma) from the frontal and parietal lobes will be detected and correlated to the individual pain rate as well as the dimensions of the psychological questionnaires.

    Time frame: 10 minutes of recording after isotonic/hypertonic injection

  3. Perturbation of the electroencephalogram (EEG) rhythms

    Electroencephalographic (EEG) recording will be performed placing a 64-electrodes cap over the scalp according to the 10-20 international system. Perturbation of the above-mentioned EEG rhythms will be measured in response to the hypertonic/isotonic saline injection and compared to a resting state baseline recording.

    Time frame: 10 minutes of recording before isotonic/hypertonic injection

  4. Perturbation of the electroencephalogram (EEG) rhythms

    Electroencephalographic (EEG) recording will be performed placing a 64-electrodes cap over the scalp according to the 10-20 international system. Perturbation of the above-mentioned EEG rhythms will be measured in response to the hypertonic/isotonic saline injection and compared to a resting state baseline recording.

    Time frame: 10 minutes of recording after isotonic/hypertonic injection

  5. Collection of blood samples

    Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.

    Time frame: time 0 (baseline)

  6. Collection of blood samples

    Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.

    Time frame: Time 1 (3 hours)

  7. Collection of blood samples

    Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.

    Time frame: time 2 (24 hours)

  8. Collection of blood samples

    Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.

    Time frame: time 3 (48 hours)

  9. Collection of blood samples

    Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected into SST™ II Advance Serum Separation Tubes containing anticoagulant EDTA.

    Time frame: time 4 (72 hours)

  10. MicroRNAs (miRNAs) expression analysis

    From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation. Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.

    Time frame: time 0 (baseline)

  11. MicroRNAs (miRNAs) expression analysis

    From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation. Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.

    Time frame: time 1 (3 hours)

  12. MicroRNAs (miRNAs) expression analysis

    From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation. Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.

    Time frame: time 2 (24 hours)

  13. MicroRNAs (miRNAs) expression analysis

    From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation. Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.

    Time frame: time 3 (48 hours)

  14. MicroRNAs (miRNAs) expression analysis

    From the blood samples previously collected, miRNA will be isolated for a subsequent miRNA library preparation. Subsequently, extracted miRNA will be reversely transcribed, and cDNA will be used for total miRNAs sequencing.

    Time frame: time 4 (72 hours)

  15. Proteome analysis

    From the blood samples previously collected, the protein concentration will be determined. Protein sequencing will be done using mass spectrometers.

    Time frame: time 0 (baseline)

  16. Proteome analysis

    From the blood samples previously collected, the protein concentration will be determined. Protein sequencing will be done using mass spectrometers.

    Time frame: time 1(3 hours)

  17. Proteome analysis

    From the blood samples previously collected, the protein concentration will be determined. Protein sequencing will be done using mass spectrometers.

    Time frame: time 2 (24 hours)

  18. Proteome analysis

    From the blood samples previously collected, the protein concentration will be determined. Protein sequencing will be done using mass spectrometers.

    Time frame: time 3 (48 hours)

  19. Proteome analysis

    From the blood samples previously collected, the protein concentration will be determined. Protein sequencing will be done using mass spectrometers.

    Time frame: time 4 (72 hours)

  20. Metabolome analysis

    From the blood samples previously collected. Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.

    Time frame: time 0 (baseline)

  21. Metabolome analysis

    From the blood samples previously collected. Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.

    Time frame: time 1(3 hours)

  22. Metabolome analysis

    From the blood samples previously collected. Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.

    Time frame: time 2 (24 hours)

  23. Metabolome analysis

    From the blood samples previously collected. Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.

    Time frame: time 3 (48 hours)

  24. Metabolome analysis

    From the blood samples previously collected. Metabolites will be investigated and identified by a 4D feature finding using Metaboscape.

    Time frame: time 4 (72 hours)

  25. Plasma cortisol levels measurement

    From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 0 (baseline)

  26. Plasma cortisol levels measurements

    From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 1(3 hours)

  27. Plasma cortisol levels measurements

    From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 2 (24 hours)

  28. Plasma cortisol levels measurements

    From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 3 (48 hours)

  29. Plasma cortisol levels measurements

    From the blood samples previously collected, plasma levels of cortisol will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 4 (72 hours)

  30. Plasma Interleukin-6 (IL-6) levels measurements

    From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 0 (baseline)

  31. Plasma Interleukin-6 levels measurements

    From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 1(3 hours)

  32. Plasma Interleukin-6 levels measurements

    From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 2 (24 hours)

  33. Plasma Interleukin-6 levels measurements

    From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 3 (48 hours)

  34. Plasma Interleukin-6 levels measurements

    From the blood samples previously collected, plasma levels of IL-6 will be evaluated through enzyme-linked immunosorbent assay (ELISA).

    Time frame: time 4 (72 hours)

Secondary outcomes

  1. Measuring Pain using VAS

    The subject will rate the pain intensity continuously for 20 minutes and VAS will start from zero (0), representing no pain, and will end at one hundred (100) representing worst pain imaginable.

    Time frame: 20 minutes

Other outcomes

  1. Pain Catastrophizing Scale (PCS) questionnaire

    The PCS assesses negative and exaggerated coping concerning anticipated or experienced painful stimuli. Thirteen items have to be answered on a 5-points Likert-type scale from 0 (non at all) to 4 (all the time).

    Time frame: time 0 (baseline)

  2. Positive and Negative Affect Schedule (PANAS) questionnaire

    The PANAS measures positive affects (PA) dimensions ( "the extent to which a person feels active, enthusiastic, and alert") and negative affects (NA) dimensions (a condition of "general distress and unpleasable engagement"). Twenty words are associated with the subject's current feelings and have to be rated on a 5-points Likert-type scale from 1 (non at all) to 5 (extremely).

    Time frame: time 0 (baseline)

  3. Reinforcement Sensitivity Theory - Personality Questionnaire (RST-PQ).

    The RST-PQ contains the following subscales: * Fight-Flight-Freeze System (FFFS, 10 items), related to active avoidance of adverse stimuli; * Behavioral Inhibition System (BIS, 23 items), related to anxiety and passive avoidance of adverse stimuli; * Behavioral Approach System (BAS, 32 items), it reflects reward interest, reward reactivity, impulsivity. In total, 65 items have to be answered on a 4-points Likert-type scale, from 1 (non at all) to 4 (highly).

    Time frame: time 0 (baseline)

  4. State-Trait Anxiety Inventory - Form Y (STAI-Y)

    The STAI-Y questionnaire measures two types of anxiety, the state and the trait anxiety, as well as the severity of the overall anxiety level. The questionnaire is divided into two sections of 20 items each to be rated on a 4-points Likert-type scale from 1 (non at all) to 4 (very much).

    Time frame: time 0 (baseline)

  5. Heart rate assessment

    An electrocardiogram (ECG) will be recorded with a standard 3-lead montage (one electrode on each wrist and the third on the left ankle)

    Time frame: time 0 (baseline)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2024, 26 months after the start.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 26 months is above that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2021
First posted
Mar 8, 2021
StartActual
Oct 15, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04787198
Lead sponsor
Aalborg University
Responsible party
Laura Petrini (Associate Professor, Aalborg University) — Principal investigator
First posted
Mar 8, 2021
Start date
Oct 15, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 2, 2024

Study contacts

Laura Petrini, PhD
Contact
lap@hst.aau.dk
0045 99409826
Laura Petrini, PhD
principal investigator · Aalborg University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion